Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications Neurodegenerative disorders (NDs) are increasingly common, affecting 15% of the global population. Common NDs include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). These disorders are caused by a complex interplay of genetic, environmental, and lifestyle factors, with neuroinflammation playing a significant role in their progression. Inflammation not only supports ND progression but can also initiate the disease. Anti-inflammatory drugs are being investigated as potential treatments, though clinical outcomes are often questionable. This review discusses the role of neuroinflammation in ND pathophysiology, current treatment strategies for various NDs, and the use of anti-inflammatory agents as therapeutic options. For AD, approved treatments include cholinesterase inhibitors, NMDA antagonists, antipsychotics, and monoclonal antibodies. For PD, dopamine precursors, agonists, and MAO-B inhibitors are commonly used. ALS is managed with symptom-based therapies, while HD is treated with drugs targeting chorea. Neuroinflammation is a key factor in NDs, with microglia and astrocytes contributing to inflammatory responses. Anti-inflammatory drugs such as NSAIDs, minocycline, and Hidrox have shown potential in reducing neuroinflammation and slowing disease progression in preclinical models. However, clinical trials have yielded mixed results, highlighting the need for further research. Future directions include targeting specific neuroinflammatory pathways and exploring cell-based therapies, such as neural stem cells and mesenchymal stem cells, for ND treatment. Despite progress, challenges remain in understanding the complex mechanisms of neuroinflammation and developing effective therapies for NDs.Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications Neurodegenerative disorders (NDs) are increasingly common, affecting 15% of the global population. Common NDs include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). These disorders are caused by a complex interplay of genetic, environmental, and lifestyle factors, with neuroinflammation playing a significant role in their progression. Inflammation not only supports ND progression but can also initiate the disease. Anti-inflammatory drugs are being investigated as potential treatments, though clinical outcomes are often questionable. This review discusses the role of neuroinflammation in ND pathophysiology, current treatment strategies for various NDs, and the use of anti-inflammatory agents as therapeutic options. For AD, approved treatments include cholinesterase inhibitors, NMDA antagonists, antipsychotics, and monoclonal antibodies. For PD, dopamine precursors, agonists, and MAO-B inhibitors are commonly used. ALS is managed with symptom-based therapies, while HD is treated with drugs targeting chorea. Neuroinflammation is a key factor in NDs, with microglia and astrocytes contributing to inflammatory responses. Anti-inflammatory drugs such as NSAIDs, minocycline, and Hidrox have shown potential in reducing neuroinflammation and slowing disease progression in preclinical models. However, clinical trials have yielded mixed results, highlighting the need for further research. Future directions include targeting specific neuroinflammatory pathways and exploring cell-based therapies, such as neural stem cells and mesenchymal stem cells, for ND treatment. Despite progress, challenges remain in understanding the complex mechanisms of neuroinflammation and developing effective therapies for NDs.